Royce & Associates’s Abeona Therapeutics ABEO Stock Holding History

Royce & Associates’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-5,689	Closed	-$223K	–	1014
2020 Q4	$223K	Hold	5,689	–	–	﹤0.01%	956
2020 Q3	$145K	Hold	5,689	–	–	﹤0.01%	952
2020 Q2	$415K	Hold	5,689	–	–	﹤0.01%	878
2020 Q1	$299K	Hold	5,689	–	–	﹤0.01%	885
2019 Q4	$465K	Hold	5,689	–	–	﹤0.01%	896
2019 Q3	$321K	Hold	5,689	–	–	﹤0.01%	943
2019 Q2	$680K	Hold	5,689	–	–	0.01%	872
2019 Q1	$1.05M	Hold	5,689	–	–	0.01%	853
2018 Q4	$1.01M	Hold	5,689	–	–	0.01%	855
2018 Q3	$1.82M	Hold	5,689	–	–	0.01%	846
2018 Q2	$2.28M	Hold	5,689	–	–	0.02%	807
2018 Q1	$2.04M	Hold	5,689	–	–	0.01%	846
2017 Q4	$2.25M	Sell	5,689 -3,400	-37%	-$1.41M	0.02%	819
2017 Q3	$3.87M	Sell	9,089 -3,400	-27%	-$914K	0.03%	651
2017 Q2	$2M	Hold	12,489	–	–	0.01%	840
2017 Q1	$1.56M	Hold	12,489	–	–	0.01%	915
2016 Q4	$1.51M	Sell	12,489 -2,504	-17%	-$392K	0.01%	875
2016 Q3	$2.25M	Sell	14,993 -60	-0.4%	-$5.87K	0.01%	771
2016 Q2	$888K	Hold	15,053	–	–	0.01%	932
2016 Q1	$963K	Buy	15,053 +3,067	+26%	+$203K	0.01%	933
2015 Q4	$1.01M	Buy	11,986 +9,699	+424%	+$973K	0.01%	934
2015 Q3	$232K	Buy	+2,287	New	+$304K	﹤0.01%	1097

Other funds holding ABEO

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royce & Associates's ABEO Position: Q1 2021 in Review

Royce & Associates sold out of Abeona Therapeutics (ABEO) in Q1 2021, closing a stake of 5,689 shares — an estimated $223K sold.

Royce & Associates first reported a position in ABEO in Q3 2015 and held it in 22 quarters. The position peaked at $3.87M in Q3 2017. 75 funds tracked by Wall St. Rank hold ABEO as of Q1 2021.

Royce & Associates reported no remaining Abeona Therapeutics position as of Q1 2021 after selling out during the quarter.
Royce & Associates sold 5,689 Abeona Therapeutics shares in Q1 2021, an estimated $223K.
Royce & Associates first reported a position in Abeona Therapeutics in Q3 2015 and held it in 22 quarters.
Royce & Associates's Abeona Therapeutics position peaked at $3.87M in Q3 2017.
75 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2021.

Based on Royce & Associates's 13F filing for Q1 2021, filed 10 May 2021.